| Name | Title | Contact Details |
|---|
Coffey Communications, Inc., is the leading provider of custom communication products for the health care industry. For more than 19 years, we have been providing clients with a full line of communication tools including: Publications for hospitals and
Eastern Area Specialty Transport is a Winchester, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
The Integrated Health and Social Services University Network for West-Central Montreal (CIUSSS West-Central Montreal) is one of the largest health and social services network in the Montreal area, regrouping over 20 establishments in the west end of Montreal and serving a population of nearly 345,000. We are making the difference, one person at a time. CIUSSS West-Central Montreal`s services and programs span the continuum of healthcare, from hospital to community integrated services to residential care. Our 9,000 employees, including 900 doctors, are guided by values of compassion, integrity and commitment to the quality of care. We are proud of our official bilingual status and the culturally rich identities of our sites. On top of clinical activities, research and teaching play an integral part in the CIUSSS West-Central Montreal network.